Overview

PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections

Status:
Completed
Trial end date:
2008-11-20
Target enrollment:
Participant gender:
Summary
This is a research study designed to look at the pharmacokinetics (distribution, breakdown, and removal) and tolerability of a single dose of daptomycin in patients aged 2 to 6 years who have infections that are caused by a specific group of bacteria (called Gram-positive bacteria).
Phase:
Phase 1
Details
Lead Sponsor:
Cubist Pharmaceuticals LLC
Treatments:
Daptomycin